Analytical Data
-
基因名
SLC31A1
- Application
-
别名
Copper transporter 1 Short name: hCTR1 Solute carrier family 31 member 1
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O15431
-
表达区间
1-190aa
-
分子量
37.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC31A1, also known as the copper transporter 1 (CTR1), plays a crucial role in cellular copper homeostasis, which is vital for numerous physiological processes, including enzyme function and antioxidant defense. Dysregulation of copper levels is associated with various disorders, such as Menkes disease and Wilson's disease. Recent studies have highlighted the significance of SLC31A1 in cancer biology, where its expression may influence tumor growth and response to therapy, particularly in the context of platinum-based chemotherapy. Research into the recombinant expression of SLC31A1 protein allows for the detailed study of its structure, function, and interaction with copper ions and other ligands. This is essential for understanding its mechanism of action, which could provide insights into therapeutic strategies for metal ion-related diseases and enhance the effectiveness of cancer treatments by elucidating the role of copper transport in tumor metabolism. Furthermore, identifying small molecules that can modulate SLC31A1 activity may pave the way for novel interventions in copper-related pathologies and cancer therapy. Overall, the study of SLC31A1 through recombinant protein technology is a promising avenue for enhancing our understanding of metal ion transport and its implication in health and disease.
